Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study
This study highlights the relative safety of therapies approved for the management of hemophilia A and B. While more ADRs were reported with emicizumab, no inhibitor development was observed. However, novelty bias cannot be ruled out. Our estimates are limited by the use of routinely collected data with no adjustment for confounding due to low event rates and missing data.
Authors
- Lawrence C. E. Mbuagbaw (ORCID: https://orcid.org/0000-0001-5855-5461)
- Emma Iserman (ORCID: https://orcid.org/0000-0001-7539-6490)
- Alfonso Iorio (ORCID: https://orcid.org/0000-0002-3331-8766)
- Federico Germini (ORCID: https://orcid.org/0000-0002-0802-3616)
- Jean‐Éric Tarride (ORCID: https://orcid.org/0000-0003-2913-7580)
- Davide Matino (ORCID: https://orcid.org/0000-0002-9902-4074)
- Mark Belletrutti (ORCID: https://orcid.org/0000-0002-7795-1862)
- Omotola O Olasupo (ORCID: https://orcid.org/0000-0002-8755-1280)
- Michelle Bech
- Shannon Jackson
- Arun Keepanasseril (ORCID: https://orcid.org/0000-0003-0733-9616)
- Ingrid Blydt-Hansen
- C. H. Woo
- Zainab Salim Ali Al-Housni
- Quazi Ibrahim
Institutions
- Humanitas University (IT)
- University of British Columbia (CA)
- St. Paul's Hospital (CA)
- St. Paul's Hospital (CA)
- Impact (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- McMaster University (CA)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1016/j.rpth.2025.103280
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Bayer
- Sanofi
- BioCryst
- Novo Nordisk
- Takeda Canada
- Canadian Institutes of Health Research
- Principia Biopharma